Resonance Health Limited (ASX:RHT)


right-arrow Created with Sketch. 0.005 (3.13%)
MCAP $73.78M
Last trade 15.46pm 27/01/2022 20mins delayed

Latest Announcements

14.37pm 27/01/2022 Price SensitivePSRHTResonance Health Limited
25/01/2022 Price SensitivePSRHTResonance Health Limited
18/01/2022RHTResonance Health Limited
30/12/2021 Price SensitivePSRHTResonance Health Limited
20/12/2021 Price SensitivePSRHTResonance Health Limited
03/12/2021 Price SensitivePSRHTResonance Health Limited
29/11/2021RHTResonance Health Limited
25/11/2021RHTResonance Health Limited

Company Overview

Resonance Health Limited is an Australian healthcare company. The Company is focused on the development and commercialization of technologies and services for the analysis of radiological images. The Company's core product is FerriScan, which is a non-invasive liver diagnostic technology used for the measurement of iron in the liver. FerriScan uses Artificial Intelligence (AI) as an automated software medical device to determine liver iron concentration (LIC) measurement from magnetic resonance imaging (MRI) scans of a patient's liver. The Company product HepaFat-Scan is a non-invasive MRI-based solution for measuring the volume fraction of fat in liver tissue. HepaFat-Scan is a medical device software, which is fully automated and uses Artificial Intelligence (AI) to assess liver fat. HepaFat-AI assesses and reports the volumetric liver fat fraction (VLFF), proton density fat fraction (PDFF), and steatosis grade in individuals with suspected fatty liver disease.

RHT in the news

Resonance Health (RHT) has been contracted to provide liver-fat quantification services for…
Resonance Health (RHT) receives United States Food & Drug Administration (FDA) for…
Resonance Health (RHT) submits its LiverSmart device to the FDA for US…
Resonance Health (RHT) signs an agreement with Thalassaemia International Federation (TIF) to…

Search Previous Announcements